A Robust Pipeline Powered by Modality-Agnostic Targeted Oncology
Taking a modality-agnostic approach offers incredible freedom to develop the most effective cancer therapies. Our programs range from engineered therapeutic proteins to innovative monoclonal antibodies, as well as kinase inhibitors and protein degraders, designed to target both the tumor and tumor microenvironment.
Patients also need more tolerable cancer treatments. We employ strategies to improve tumor response, minimize toxicity, and allow more patient-friendly dosing.